Clinical Trials Logo

de Novo clinical trials

View clinical trials related to de Novo.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02067143 Completed - Secondary Clinical Trials

MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate

LAL1913
Start date: May 20, 2014
Phase: Phase 2
Study type: Interventional

This study will be conducted in different centres and will study adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). The study treatment will include a induction/consolidation therapy incorporating pegylated Asparaginase (Peg-ASP) and lineage-targeted high-dose methotrexate plus other antileukemic drugs, for the achievement of an early negative minimal residual disease (MRD) status. The MRD study supports a risk/MRD-oriented final consolidation phase.